首页 | 本学科首页   官方微博 | 高级检索  
检索        

重症心脏瓣膜病患者术前应用含磷酸肌酸心肌极化液的作用
引用本文:石开虎,龚文辉,张飞,吴君旭,徐盛松,曹炜,宣海洋.重症心脏瓣膜病患者术前应用含磷酸肌酸心肌极化液的作用[J].中国基层医药,2011,18(18):2451-2452.
作者姓名:石开虎  龚文辉  张飞  吴君旭  徐盛松  曹炜  宣海洋
作者单位:安徽医科大学心血管病研究中心安徽医科大学第二附属医院心胸外科,安徽省合肥,230601
摘    要:目的探讨重症心脏瓣膜病术前使用含磷酸肌酸的心肌极化液对瓣膜置换术患者心肌的保护作用。方法126例心脏瓣膜病患者随机分为普通极化液(对照组)和含磷酸肌酸极化液(观察组)两组。对患者手术情况及术后恢复情况等指标进行对比。结果两组患者体外循环时间、主动脉阻断时间及病死率差异均无统计学意义(均P〉0.05)。观察组术后肌酸激酶同工酶(21.36±9.21)U/L,肌钙蛋白I(0.83±0.35)ng/ml,均较对照组明显下降;观察组心律失常发生率(37.1%)较对照组(57.8%)明显减低(x2=5.418,P〈0.05);观察组心脏自动复跳率、术后24h的心脏指数、射血分数亦明显高于对照组,而术后住院时间明显缩短(均P〈0.05)。结论瓣膜置换术前应用含磷酸肌酸极化液能有效减轻术后心肌缺血再灌注损伤,有明显心肌保护作用,可降低心律失常发生率,提高患者术后的心功能。

关 键 词:心脏瓣膜病  极化液  磷酸肌酸

The value of creatine phosphate GIK in cardiac valve disease before operation
SHI Kai-hu,GONG Wen-hui,ZHANG Fei,WU Jun-xu,XU Sheng-song,CAO Wei,XUAN Hai-yang.The value of creatine phosphate GIK in cardiac valve disease before operation[J].Chinese Journal of Primary Medicine and Pharmacy,2011,18(18):2451-2452.
Authors:SHI Kai-hu  GONG Wen-hui  ZHANG Fei  WU Jun-xu  XU Sheng-song  CAO Wei  XUAN Hai-yang
Institution:. Department of Cardiovascular Disease Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei,Anhui 230601, China
Abstract:Objective To investigate the myocardial protection on cardiac valve replacement surgery with creatine phosphate of myocardial GIK (GIK) in order to reduce the surgical risk and improving the efficacy.Methods 126 cases were unergone surgical treatment of heart valve disease,whose cardiac function on admission wereⅢor Ⅳ. 126 patients were randomly divided into two groups. Cardiopulmonary bypass time, aortic cross clamp time, postoperative myocardial injury markers ( CK-MB, cTNI) changes, arrhythmias, heart function recovery, length of stay and mortality rate and other indicators were compared between the two groups. Results The age, gender, body mass,heart disease and surgery combined data were not statistically significant between the two groups( all P >0. 05). The cardiopulmonary bypass time, aortic cross clamp time and mortality had no significant differences between the two groups( all P > 0.05 ). The CK-MB( 21.36± 9.21 ) U/L and cTNI(0.83 ± 0. 35 ) ng/ml of creatine phosphate group were significantly lower than those of the control group. The incidence of arrhythmia in phosphocreatine group (37. 1% ) was significantly lower than ordinary group (57.8 % ) ( X2 = 5. 418, P < 0. 05 ). Conclusion The application of creatine phosphate GIK before valve replacement surgery could effectively reduce reperfusion injury after myocardial ischemia,myocardial protection,and significantly reduce the incidence of arrhythmia and improve heart function in patients.
Keywords:Heart valve disease  GIK liquid  Phosphocreatine
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号